GlassScriptPhysician profile
Brittany M Nye
NPI 1235600719
$2,125.41
in general payments reported to CMS, 2019-2025
24 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $469 · 2022: $513 · 2023: $302 · 2024: $445 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.89 | 2021-2025 | |
| Abbott Laboratories | $312.06 | 2021-2025 | Freestyle Libre, Infinity |
| Bayer Healthcare Pharmaceuticals INC. | $294.10 | 2021-2025 | |
| Lilly USA, LLC | $166.06 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Nestle Healthcare Nutrition INC. | $119.06 | 2021 | |
| Stryker Corporation | $118.24 | 2022 | |
| Lundbeck LLC | $111.89 | 2024-2025 | Rexulti, Vyepti |
| Otsuka America Pharmaceutical, INC. | $72.25 | 2021-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.36 | 2021-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $60.40 | 2022-2025 | Airsupra |
| Dexcom, INC. | $56.78 | 2022-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $49.52 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $41.01 | 2022-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $33.48 | 2024 | Spravato |
| Kowa Pharmaceuticals America, INC. | $29.57 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.12 | 2025 | Veozah |
| Amgen INC. | $27.93 | 2021-2025 | Otezla, Repatha |
| Novo Nordisk INC | $26.22 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $26.08 | 2021 | |
| Bausch Health US, LLC | $25.82 | 2021-2022 | |
| Glaxosmithkline, LLC. | $23.35 | 2023 | Trelegy Ellipta |
| Corium, LLC | $21.64 | 2022 | |
| Alkermes, INC. | $19.08 | 2023 | Lybalvi |
| Amarin Pharma, INC. | $15.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Nye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.